Restricted accessResearch articleFirst published online 2023-02
Elevated Serum Low-Density Lipoproteins-Cholesterol Levels and B1B2/B2B2 CETP Genotype Are Positively Associated with Nonalcoholic Fatty Liver Disease in Women with Gallstone Disease
Nonalcoholic fatty liver disease (NAFLD) is generated by the interaction between environmental and genetic factors, and the presence of metabolic alterations. Since Taq1B cholesteryl ester transfer protein (CETP) polymorphism is associated with abnormal serum lipid values, it could be related to NAFLD. The aim of this study was to determine the role of the Taq1B CETP polymorphism with serum lipids, anthropometric variables, and the extent of steatosis in Mexican-mestizo women with gallstone disease (GD).
Methods:
Sixty-two women were enrolled in this cross-sectional study. Serum lipids were determined by dry chemistry. The Taq1B CETP polymorphism was determined by allelic discrimination. CETP serum levels were measured by enzyme-linked immunosorbent assay, and the extent of steatosis with a biopsy staining with Oil-Red-O.
Results:
Subjects with the B1B2/B2B2 genotype had higher percentage of degree of steatosis than those with B1B1 (11.95% vs. 2.19%, P = 0.008). The B1B2/B2B2 genotype (odds ratio [OR] 3.90 [confidence interval {CI} 95% 1.891–8.536], P = 0.04) and an elevated low-density lipoproteins (LDL)-cholesterol (OR 3.54 [CI 95% 1.042–2.058, P = 0.039) significantly increase the risk for NAFLD.
Conclusions:
This study provides evidence that the B1B2/B2B2 genotype of CETP and the elevated LDL-cholesterol serum levels increase the risk of NAFLD in women with GD.
Get full access to this article
View all access options for this article.
References
1.
Briseño-BassP, Chávez-PérezR, López-ZendejasM. Prevalence and relationship of hepatic steatosis with lipid profile and hepatic in patients undergoing medical check-up [in Spanish]. Rev Gastroenterol México, 2019; 84(3):290–295; doi: 10.1016/j.rgmx.2018.05.007
2.
ShekaAC, AdeyiO, ThompsonJ, et al.Nonalcoholic steatohepatitis: A review. JAMA, 2020; 323(12):1175–1183; doi: 10.1001/jama.2020.2298
3.
YounossiZ, AnsteeQM, MariettiM, et al.Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018; 15(1):11–20; doi: 10.1038/nrgastro.2017.109
4.
Neuschwander-TetriBA, CaldwellSH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatol Baltim Md, 2003; 37(5):1202–1219; doi: 10.1053/jhep.2003.50193
5.
EkstedtM, FranzénLE, MathiesenUL, et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatol Baltim Md, 2006; 44(4):865–873; doi: 10.1002/hep.21327
6.
Sepulveda-VillegasM, RomanS, Rivera-IñiguezI, et al.High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. PLoS One, 2019; 14(1):e0208926; doi: 10.1371/journal.pone.0208926
7.
MarraF, LotersztajnS. Pathophysiology of NASH: Perspectives for a targeted treatment. Curr Pharm Des, 2013; 19(29):5250–5269; doi: 10.2174/13816128113199990344
WangY, Van der TuinS, TjeerdemaN, et al.Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. Hepatol Baltim Md, 2015; 62(6):1710–1722; doi: 10.1002/hep.27985
12.
ThompsonA, Di AngelantonioE, SarwarN, et al.Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA, 2008; 299(23):2777–2788; doi: 10.1001/jama.299.23.2777
13.
MaroufiNF, FarzanehK, AlibabrdelM, et al.Taq1B polymorphism of cholesteryl ester transfer protein (CETP) and its effects on the serum lipid levels in metabolic syndrome patients. Biochem Genet, 2016; 54(6):894–902; doi: 10.1007/s10528-016-9766-5
14.
LiTY, ZhangC, AsselbergsFW, et al.Interaction between dietary fat intake and the cholesterol ester transfer protein TaqIB polymorphism in relation to HDL-cholesterol concentrations among US diabetic men. Am J Clin Nutr, 2007; 86(5):1524–1529; doi: 10.1093/ajcn/86.5.1524
15.
National Institutes of Health. What's at-risk or heavy drinking?—Rethinking Drinking—NIAAA; 2019. Available from: https://www.rethinkingdrinking.niaaa.nih.gov/how-much-is-too-much/is-your-drinking-pattern-risky/whats-at-risk-or-heavy-drinking.aspx [Last accessed: December 6, 2021].
16.
Marfell-JonesM, StewartA, OldsT, et al. International Standards for Anthropometric Assessment: (2011). International Society for the Advancement of Kinanthropometry: New Zealand; 2011.
17.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18(6):499–502; doi: 10.1093/clinchem/18.6.499
18.
StoneNJ, RobinsonJG, LichtensteinAH, et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63(25 Part B):2889–2934; doi: 10.1016/j.jacc.2013.11.002
19.
BruntEM, TiniakosDG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol, 2010; 16(42):5286–5296; doi: 10.3748/wjg.v16.i42.5286
SandhoferA, TatarczykT, LaimerM, et al.The Taq1B-variant in the cholesteryl ester-transfer protein gene and the risk of metabolic syndrome. Obes Silver Spring Md, 2008; 16(4):919–922; doi: 10.1038/oby.2007.130
22.
The World Medical Association-WMA Declaration of Helsinki—Ethical Principles for Medical Research Involving HumanSubjects, World medical association; 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ [Last accessed: July 23, 2020].
EverhartJE, KhareM, HillM, et al.Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology, 1999; 117(3):632–639; doi: 10.1016/s0016-5085(99)70456-7
25.
SunH, TangH, JiangS, et al.Gender and metabolic differences of gallstone diseases. World J Gastroenterol, 2009; 15(15):1886–1891; doi: 10.3748/wjg.15.1886
26.
Díaz-RosalesJdeD, Enríquez-DomínguezL, Díaz-TorresB. Risk factors for non-alcoholic fatty liver in patients with symptomatic cholelithiasis [in Spanish]. Arch Med Col, 2016; 16(1):98–108; doi: 10.3055/4/archmed.16.1.1563.2016
27.
WattacherilJ, IssaD, SanyalA. Nonalcoholic steatohepatitis (NASH) and hepatic fibrosis: Emerging therapies. Annu Rev Pharmacol Toxicol, 2018; 58:649–662; doi: 10.1146/annurev-pharmtox-010617-052545
28.
LoriaP, LonardoA, LombardiniS, et al.Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors. J Gastroenterol Hepatol, 2005; 20(8):1176–1184; doi: 10.1111/j.1440-1746.2005.03924.x
29.
Escobedo de la PeñaJ, Jesus-PérezR, SchargrodskyH, et al.Prevalence of dyslipidemias in Mexico City and its association with other cardiovascular risk factors. Results of the CARMELA study [in Spanish]. Gac Médica México, 2014; 150(2):128–136.
30.
SalinasCAA, PérezFJG, GarberIL, et al.Diagnosis and treatment of dyslipidemias: position of the Society Mexican Nutrition and Endocrinology [in Spanish]. Rev Endocrinol Nutr, 2004; 12(1):7–41.
31.
HayatS, HassanZ, ChangaziSH, et al.Comparative analysis of serum lipid profiles in patients with and without gallstones: A prospective cross-sectional study. Ann Med Surg, 2019; 42:11–13; doi: 10.1016/j.amsu.2019.04.003
32.
MarcelYL, McPhersonR, HogueM, et al.Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest, 1990; 85(1):10–17; doi: 10.1172/JCI114397
33.
McPhersonR, MannCJ, TallAR, et al.Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb J Vasc Biol, 1991; 11(4):797–804; doi: 10.1161/01.atv.11.4.797
34.
BlauwLL, Li-GaoR, NoordamR, et al.CETP (cholesteryl ester transfer protein) concentration: A genome-wide association study followed by mendelian randomization on coronary artery disease. Circ Genom Precis Med, 2018; 11(5):e002034; doi: 10.1161/CIRCGEN.117.002034
35.
ShimadaA, KimuraH, OidaK, et al.Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association. Lipids Health Dis, 2016; 15:57; doi: 10.1186/s12944-016-0223-6
36.
TatoF, VegaGL, GrundySM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients. Role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol, 1997; 17(1):56–63; doi: 10.1161/01.atv.17.1.56
37.
SchaeferEJ, LevyRI, AndersonDW, et al.Plasma-triglycerides in regulation of H.D.L.-cholesterol levels. Lancet Lond Engl, 1978; 2(8086):391–393; doi: 10.1016/s0140-6736(78)91863-9
38.
DavisCE, GordonD, LaRosaJ, et al.Correlations of plasma high-density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations. Circulation, 1980; 62(4 Pt 2):IV24–IV30.
39.
RichardsEG, GrundySM, CooperK. Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol, 1989; 63(17):1214–1220; doi: 10.1016/0002-9149(89)90181-1
40.
DeckelbaumRJ, GranotE, OschryY, et al.Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arterioscler Dallas Tex, 1984; 4(3):225–231; doi: 10.1161/01.atv.4.3.225
MannCJ, YenFT, GrantAM, et al.Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest, 1991; 88(6):2059–2066; doi: 10.1172/JCI115535
43.
BorggreveSE, HillegeHL, WolffenbuttelBHR, et al.The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab, 2005; 90(7):4198–4204; doi: 10.1210/jc.2005-0182
44.
DullaartRPF, SluiterWJ. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics, 2008; 9(6):747–763; doi: 10.2217/14622416.9.6.747
45.
CriquiMH, HeissG, CohnR, et al.Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med, 1993; 328(17):1220–1225; doi: 10.1056/NEJM199304293281702
46.
Campos-PerezW, Perez-RoblesM, Torres-CastilloN, et al.Physical inactivity and excessive sucrose consumption are associated with higher serum lipids in subjects with Taq1B CETP polymorphism. J Hum Nutr Diet Off J Br Diet Assoc, 2020; 33(3):299–307; doi: 10.1111/jhn.12747
47.
Cahua-PabloJÁ, CruzM, Méndez-PalaciosA, et al.Polymorphisms in the LPL and CETP genes and haplotype in the ESR1 gene are associated with metabolic syndrome in women from Southwestern Mexico. Int J Mol Sci, 2015; 16(9):21539–21554; doi: 10.3390/ijms160921539
48.
AllerR, IzaolaO, PrimoD, et al.Cholesteryl ester transfer protein variant (RS1800777) with liver histology in non-alcoholic fatty liver disease patients. Ann Nutr Metab, 2018; 73(4):265–270; doi: 10.1159/000493552
49.
ElsammakMY, Al-SharkaweeyRM, FahmyM, et al.Taq1B polymorphism of cholesteryl ester transfer protein (CETP) in Egyptian patients with metabolic syndrome. Diabetes Metab Syndr, 2011; 5(2):61–65; doi: 10.1016/j.dsx.2010.12.009
50.
Porchay-BaldérelliI, PéanF, BelliliN, et al.The CETP TaqIB polymorphism is associated with the risk of sudden death in type 2 diabetic patients. Diabetes Care, 2007; 30(11):2863–2867; doi: 10.2337/dc07-0869
51.
CorellaD, SáizC, GuillénM, et al.Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis, 2000; 152(2):367–376; doi: 10.1016/s0021-9150(99)00477-3
52.
HassanzadehT, FiroozraiM, ZonouzAE, et al.Taq1B polymorphism of cholesteryl ester transfer protein (CETP) gene in primary combined hyperlipidaemia. Indian J Med Res, 2009; 129(3):293–298; doi: 10.1007/s10528-016-9766-5
53.
LinZhu, ThaoLuu, ChristopherH. Emfinger, et al. CETP inhibition improves HDL function but leads to fatty liver and insulin resistance in CETP-expressing transgenic mice on a high-fat diet. Diabetes, 2018; 67(12):2494–2506; doi: 10.2337/db18-0474
54.
PalmisanoBT, LeTD, ZhuL, et al.Cholesteryl ester transfer protein alters liver and plasma triglyceride metabolism through two liver networks in female mice. J Lipid Res, 2016; 57(8):1541–1551; doi: 10.1194/jlr.M069013
55.
CappelDA, PalmisanoBT, EmfingerCH, et al.Cholesteryl ester transfer protein protects against insulin resistance in obese female mice. Mol Metab, 2013; 2(4):457–467; doi: 10.1016/j.molmet.2013.08.007
56.
GambinoR, CassaderM, PaganoG, et al.Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?. Hepatol Baltim Md, 2007; 45(5):1097–1107; doi: 10.1002/hep.21631
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
